These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9553995)

  • 41. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
    Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
    Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
    [No Abstract]   [Full Text] [Related]  

  • 42. [Bromperidol decanoate in the residual phase of schizophrenia].
    Smeraldi E; Cocconcelli C; Canova L; Faravelli C; Marchetti FP; Mariani G; Rapisarda V
    Minerva Psichiatr; 1996 Mar; 37(1):39-44. PubMed ID: 8926856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene.
    Mihara K; Kondo T; Suzuki A; Yasui N; Nagashima U; Ono S; Otani K; Kaneko S
    Psychopharmacology (Berl); 2000 Apr; 149(3):246-50. PubMed ID: 10823405
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radioimmunoassay of bromperidol and haloperidol in human and canine plasma.
    Van Den Eeckhout E; Belpaire FM; Bogaert MG; De Moerloose P
    Eur J Drug Metab Pharmacokinet; 1980; 5(1):45-8. PubMed ID: 7389751
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs.
    Woggon B
    Acta Psychiatr Belg; 1978; 78(1):155-72. PubMed ID: 347878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
    Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
    Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatment with bromperidol in schizophrenic patients].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1989; 35(1-2):23-30. PubMed ID: 2634329
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia.
    Rao VA; Bishop M; Coppen A
    Br J Psychiatry; 1980 Dec; 137():518-21. PubMed ID: 7214106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A study of serum prolactin levels in schizophrenia: comparison of males and females.
    Kuruvilla A; Peedicayil J; Srikrishna G; Kuruvilla K; Kanagasabapathy AS
    Clin Exp Pharmacol Physiol; 1992 Sep; 19(9):603-6. PubMed ID: 1356671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.
    Yasui-Furukori N; Saito M; Tsuchimine S; Nakagami T; Sato Y; Sugawara N; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1491-5. PubMed ID: 18579277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Possible interaction between cisapride and bromperidol.
    Ishida M; Otani K; Yasui N; Inoue Y; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 Jan; 21(1):235-8. PubMed ID: 9075269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses.
    Benfield P; Ward A; Clark BG; Jue SG
    Drugs; 1988 Jun; 35(6):670-84. PubMed ID: 3048975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
    David SR; Taylor CC; Kinon BJ; Breier A
    Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
    Eklund K; Forsman A
    Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment with bromperidol in schizophrenic patients].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1988 Dec; 34(4):335-40. PubMed ID: 2908218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin.
    Kondo T; Ishida M; Tokinaga N; Mihara K; Yasui-Furukori N; Ono S; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):287-91. PubMed ID: 11817505
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gender differences in prolactin elevation induced by olanzapine in Japanese drug-naïve schizophrenic patients.
    Sawamura K; Suzuki Y; Fukui N; Sugai T; Someya T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1511-4. PubMed ID: 16824658
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analytical methods for the determination of bromperidol in plasma.
    Van den Eeckhout E; Belpaire F
    Acta Psychiatr Belg; 1978; 78(1):64-8. PubMed ID: 645408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Results of a clinical trial with bromperidol C-C 2489/21.
    Weiser G
    Acta Psychiatr Belg; 1978; 78(1):102-9. PubMed ID: 347873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.